EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...
Nandita Vijayasimha, Bengaluru Wednesday, January 29, 2025, 08:00 Hrs [IST] ...
Indian pharma faces decline in R&D productivity, patent expiries, turns to AI to mitigate challenges
Nandita Vijayasimha, Bengaluru Wednesday, January 29, 2025, 08:00 Hrs [IST] ...
SEC asks SII to submit more data for approval of recombinant mAB for dengue treatment in adults: Our Bureau, New Delhi Wednesday, January 29, 2025, 08:00 Hrs [IST] The Subject Exp ...
Gireesh Babu, New Delhi Wednesday, January 29, 2025, 08:00 Hrs [IST] ...
DGFT grants relief in average export obligation under EPCG Scheme: Shardul Nautiyal, Mumbai Wednesday, January 29, 2025, 08:00 Hrs [IST] The Directorate General of Foreign Trade ( ...
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...
Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...
ManipalCigna Health Insurance drives awareness with free health checkup camps: Our Bureau, Bengaluru Tuesday, January 28, 2025, 17:15 Hrs [IST] ManipalCigna Health Insurance in co ...
An all-new participant recruitment and retention SaaS solution for clinical trials: Princeton, New Jersey Tuesday, January 28, 2025, 18 ...
Confluence of modern medicine and technology discussed at PIWOT-2025 in Mumbai: Our Bureau, Mumbai Tuesday, January 28, 2025, 16:15 Hrs [IST] Leading experts from healthcare, medi ...
Lupin and Avas launch NaMuscla in Italy to treat myotonia in adults with NDM disorders: Our Bureau, Mumbai Tuesday, January 28, 2025, 16:45 Hrs [IST] Global pharma major Lupin Lim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback